Compare NBHC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | ZYME |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2011 | 2022 |
| Metric | NBHC | ZYME |
|---|---|---|
| Price | $41.25 | $27.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $47.67 | $38.90 |
| AVG Volume (30 Days) | 298.8K | ★ 640.7K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 1.04 | N/A |
| Revenue | $47,100,000.00 | ★ $105,965,000.00 |
| Revenue This Year | $39.96 | $183.10 |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | $40.16 | ★ N/A |
| Revenue Growth | 2.86 | ★ 38.87 |
| 52 Week Low | $35.06 | $15.26 |
| 52 Week High | $47.28 | $31.34 |
| Indicator | NBHC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 39.49 | 50.65 |
| Support Level | $40.47 | $22.26 |
| Resistance Level | $42.74 | $29.75 |
| Average True Range (ATR) | 0.61 | 1.62 |
| MACD | 0.06 | -0.15 |
| Stochastic Oscillator | 43.48 | 31.25 |
National Bank Holdings Corp offers a full range of banking products and financial services to commercial, business, and consumer clients predominantly in Colorado, with a focus on personalized service through relationship managers and banking center associates. The company provides commercial and industrial loans, non-owner occupied commercial real estate loans, Small Business Administration loans as a Preferred Lender Provider, U.S. Department of Agriculture and Farm Service Agency loans, commercial deposit and treasury management products, business online and mobile banking, consumer and residential real estate loans, deposit services, and trust and wealth management services. Its services emphasize full-relationship banking, integrating lending, deposits, and cash management solutions.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.